The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 23 | 42.6x | 20.3x | Below average | |
Growth | 84 | 47.4% | 5.6% | Above average | |
Quality | 76 | 54.0% | 7.6% | Above average | |
Safety | 67 | 1.0x | 0.4x | Near average | |
Capital Return | 23 | 0.52% | 2.15% | Below average | |
Momentum | 82 | — | — | Above average | |
Sentiment | 69 | — | — | Above average |
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Eli Lilly and Company (LLY) is a global leader in the healthcare and innovative pharmaceuticals sector, focusing on discovering, developing, and manufacturing cutting-edge therapies in key areas including cardiovascular and metabolic diseases (diabetes and obesity), immunology, neuroscience, and oncology. The company generates its revenue by selling prescription drugs through traditional and digital distribution channels, including its innovative LillyDirect platform, as well as commercial and government healthcare channels worldwide.
During the first quarter of 2026, the company achieved very strong financial results, with revenue jumping by 56% to reach $19.8 billion compared to the first quarter of 2025, driven by the massive growth of its key products, particularly Mounjaro and Zepbound, which generated combined sales of $12.8 billion. The gross margin for the first quarter was 82.6%, while net income reached $7.4 billion, with earnings per share of $8.26 (or $8.55 per share on a non-GAAP basis), and the company achieved an operating margin of 50%, representing an increase of 7 percentage points.
The stock is currently trading at $1151.5, which is below the average analyst target of $1266.17 (by 10.0%), with a buy consensus.
Koundeo (generic name orforglipron) is an innovative molecule recently approved by the US Food and Drug Administration (FDA) as the first oral treatment (pill) dedicated to obesity and weight management without food or water restrictions. Its strategic importance lies in the fact that it simplifies the large-scale manufacturing and distribution process compared to injections, and the company plans to submit it for the treatment of type 2 diabetes in the United States in the second quarter of 2026 following successful ACHIEVE IV trial results.
Eli Lilly achieved revenue of $19.8 billion in the first quarter of 2026, representing a massive 56% growth compared to the first quarter of 2025. Net income also rose to reach $7.4 billion with earnings per share of $8.26, supported by strong sales in the metabolic and diabetes segment, which reached $12.8 billion for Mounjaro and Zepbound combined.
The company raised its full-year 2026 financial outlook, now expecting annual revenue to range between $82 billion and $85 billion (an increase of $2 billion from previous guidance). Additionally, the non-GAAP earnings per share guidance was raised to be between $35.50 and $37.00 per share, reflecting strong confidence in the continuation of sales momentum.
Automated analysis for informational purposes only — not investment advice.
The US government announced the extension of the Medicare GLP-1 bridge program to begin coverage no later than July 1, 2026, and continue through December 2027, allowing seniors to access treatment with a maximum out-of-pocket cost of $50 per month. This program will significantly enhance patients' continuity of therapy and increase sales volume over the long term, despite the slight negative impact of Medicaid in some states.
The company announced agreements to acquire four vital companies: Orna Therapeutics to develop CAR T-cell therapies for autoimmune diseases, Syntessa Pharmaceuticals, a leader in sleep disorder treatments, Colonia Therapeutics, which has a promising platform for multiple myeloma treatment, and Ajax Therapeutics to develop JAK inhibitors for leukemia treatments.